Cencora, Inc.

NYSE:COR

Medical - Distribution

Healthcare
$348.31 -2.04%

-$5.65 today

Market cap
$66.47B
Beta
0.59
P/E (TTM)
20.7
EPS (TTM)
$13.10
Dividend yield
0.87%
52W Low $244.82High $377.54

Volume 1.20M

Average 1.78M

COR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Cencora, Inc.NYSE: COR

Investing Cash Flow · Q3 FY2026 · quarter ended Jun 2026

Investing cash flow grows, but more slowly than its trailing trend

Q3 FY2026 investing cash flow of $240.15M (cash outflow) rose 2.3% year over year, behind the +17.1% change in trailing-twelve-month investing cash flow. Sequentially, it fell 95.1% from the prior quarter. Over 3 fiscal years it compounded at +138.2% a year.

Context

  • Investing cash flow amounted to 1.5% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Investing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +17.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$240.15M-95.1% QoQ
Last fiscal yearSep 2025
-$4.98B+705.3% YoY
LTMJun 2026
-$5.74B+17.1% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%——
1 year+705.3%——
3-year CAGR+138.2%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(4.98B) USD
Year-over-year change
-705.3%

Investing Cash Flow vs competitors

How COR compares with its peers on the latest reported figures

  • COR's LTM Jun 2026 investing cash flow of $5.74B is the largest of the 5 companies compared; the peer median is $206.5M.
  • Its year-over-year change of +17.1% is the 2nd highest of 5, against a peer median of -34.2%.
  • Investing cash flow amounts to 1.7% of revenue for COR, versus a peer median of 1.7%.
COR Competitors Peer median
Investing Cash Flow for COR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CORCencora, Inc.LTM Jun 2026$5.74B +17.1%+138.2%1.7%
CAHCardinal Health, Inc.LTM Sep 2026$2.69B -52.4%+78.5%1.0%
HSICHenry Schein, Inc.LTM Jun 2026$331M -16.0%+20.0%2.4%
ACHAccendra Health, Inc.LTM Mar 2026$246.55M +251.4%—9.1%
MCKMcKesson CorporationLTM Jun 2026$82M -98.1%+85.0%0.0%
Peer median (excluding COR) $206.5M-34.2%+78.5%1.7%

Competitors are the stored peer set for COR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income1.54B1.67B1.75B1.52B1.57B
Depreciation & Amortization514.79M709.84M980.85M1.12B1.07B
Deferred Income Tax334.87M196.18M(118.86M)(102.32M)59.86M
Stock-Based Compensation99.59M93.4M124.62M148M147.96M
Change in Working Capital367.32M(139.66M)874.54M298.69M35.42M
Accounts Receivables(930.08M)(1.66B)(2.71B)(2.78B)(1.92B)
Inventory(1.12B)(665.37M)(2.18B)(1.48B)(1.27B)
Accounts Payables2.05B3.32B6.1B4.97B3.69B
Other Working Capital364.58M(1.14B)(333.76M)(405.47M)(465.1M)
Other Non-Cash Items(194.59M)176.79M304.89M502.21M995.64M
Operating Cash Flow2.67B2.7B3.91B3.48B3.88B
Capital Expenditures(438.22M)(496.32M)(458.36M)(487.17M)(667.98M)
Acquisitions (Net)(5.73B)120.28M(2.15B)(100.2M)(4.29B)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities22.3M7.6M9M(30.72M)(17.44M)
Investing Cash Flow(6.14B)(368.44M)(2.6B)(618.1M)(4.98B)
Debt Repayment2.22B(923.1M)(623.26M)(385.45M)3.2B
Common Stock Issued198.75M93.91M61.15M37.84M29.13M
Common Stock Repurchased(82.15M)(483.7M)(1.18B)(1.49B)(435.47M)
Dividends Paid(366.65M)(391.69M)(398.75M)(416.17M)(437.08M)
Other Financing Activities(13.66M)(48.2M)(80.69M)(75.85M)(103.14M)
Financing Cash Flow1.95B(1.75B)(2.22B)(2.33B)2.25B
Effect of Forex Changes(3.73M)(57.85M)72.76M9.4M(50.27M)
Net Change in Cash(1.53B)523.41M(840.65M)544.99M1.1B
Free Cash Flow2.23B2.21B3.45B3B3.21B

Cencora, Inc.

NYSE:COR

Intrinsic Alpha fair value

Locked

Current Price

$348.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.